Cardiol Therapeutics Files May 2025 6-K with Q1 Financials
Ticker: CRDL · Form: 6-K · Filed: May 14, 2025 · CIK: 1702123
| Field | Detail |
|---|---|
| Company | Cardiol Therapeutics INC. (CRDL) |
| Form Type | 6-K |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, quarterly-results, biotechnology
TL;DR
Cardiol Therapeutics dropped its Q1 2025 financials in a 6-K filing. Check it out.
AI Summary
Cardiol Therapeutics Inc. filed a Form 6-K on May 14, 2025, reporting on its activities for the month of May 2025. The filing includes condensed interim consolidated financial statements and management's discussion and analysis for the three months ended March 31, 2025. Cardiol Therapeutics Inc. is a biological products company based in Oakville, Ontario, Canada.
Why It Matters
This filing provides investors with an update on Cardiol Therapeutics' financial performance and operational activities for the first quarter of 2025, offering insights into the company's current standing.
Risk Assessment
Risk Level: medium — As a clinical-stage biotechnology company, Cardiol Therapeutics faces inherent risks related to drug development, regulatory approvals, and market adoption.
Key Numbers
- Q1 2025 — Financial Period (The filing includes financial statements and MD&A for this period.)
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — Filer of the 6-K report
- May 14, 2025 (date) — Filing date of the 6-K
- March 31, 2025 (date) — End date of the reporting period for financial statements
- Oakville, Ontario, Canada (location) — Principal executive offices of Cardiol Therapeutics Inc.
FAQ
What specific financial results are detailed in the Condensed Interim Consolidated Financial Statements for the three months ended March 31, 2025?
The filing indicates that Exhibit 99.1 contains the Condensed Interim Consolidated Financial Statements for the three months ended March 31, 2025, but the specific figures are not detailed in the provided text.
What is the primary business of Cardiol Therapeutics Inc. according to the filing?
Cardiol Therapeutics Inc. is classified under the Standard Industrial Classification code 2836, which pertains to Biological Products (No Diagnostic Substances).
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on May 14, 2025.
What other documents are submitted as part of this 6-K filing?
In addition to the financial statements, the filing includes Management's Discussion and Analysis for the Three Months Ended March 31, 2025 (Exhibit 99.2) and Form 52-109F (Exhibit 99.3).
Where are Cardiol Therapeutics Inc.'s principal executive offices located?
The principal executive offices of Cardiol Therapeutics Inc. are located at 602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 14, 2025 regarding Cardiol Therapeutics Inc. (CRDL).